LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article: Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma.

Ormazabal Vélez, Irati / Induráin Bermejo, Juan / Espinoza Pérez, José / Imaz Aguayo, Laura / Delgado Ruiz, Marina / García-Erce, José Antonio

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

2021 Volume 60, Issue 3, Page(s) 103104

Abstract: Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as ... ...

Abstract	Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. They developed important respiratory and neurological complications. After CP infusion, neutralising antibodies were detected and viral load dissapeared in both patients leading to clinical improvement with no more Covid-19 relapse.
MeSH term(s)	Aged ; COVID-19/drug therapy ; COVID-19/immunology ; COVID-19/therapy ; Female ; Humans ; Immunization, Passive ; Male ; Middle Aged ; Recurrence ; Rituximab/therapeutic use ; gamma-Globulins/immunology ; gamma-Globulins/metabolism
Chemical Substances	gamma-Globulins ; Rituximab (4F4X42SYQ6)
Language	English
Publishing date	2021-02-19
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	2046795-3
ISSN	1878-1683 ; 1473-0502
ISSN (online)	1878-1683
ISSN	1473-0502
DOI	10.1016/j.transci.2021.103104
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1739: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.

El-Ashwah, Shaimaa / Salmanton-García, Jon / Bilgin, Yavuz M / Itri, Federico / Žák, Pavel / Weinbergerová, Barbora / Verga, Luisa / Omrani, Ali S / Silva, Maria Gomes da / Szotkowski, Tomáš / Marchetti, Monia / Buquicchio, Caterina / Nucci, Marcio / Schönlein, Martin / Farina, Francesca / Besson, Caroline / Prezioso, Lucia / Nizamuddin, Summiya / Dávila-Valls, Julio /

Martín-Pérez, Sonia / Bonuomo, Valentina / Van Doesum, Jaap / Tisi, Maria Chiara / Passamonti, Francesco / Méndez, Gustavo-Adolfo / Meers, Stef / Maertens, Johan / López-García, Alberto / Glenthøj, Andreas / Bonnani, Matteo / Rinaldi, Ikhwan / Ormazabal-Vélez, Irati / Labrador, Jorge / Kulasekararaj, Austin / Espigado, Ildefonso / Demirkan, Fatih / De Jonge, Nick / Collins, Graham P / Calbacho, Maria / Blennow, Ola / Al-Khabori, Murtadha / Adžić-Vukičević, Tatjana / Arellano, Elena / Mišković, Bojana / Mladenović, Miloš / Nordlander, Anna / Ráčil, Zdeněk / Ammatuna, Emanuele / Cordoba, Raul / Hersby, Ditte Stampe / Gräfe, Stefanie / Emarah, Ziad / Hanakova, Michaela / Sacchi, Maria Vittoria / Ijaz, Marriyam / Rahimli, Laman / Nunes Rodrigues, Raquel / Zambrotta, Giovanni Paolo Maria / Marchesi, Francesco / Cornely, Oliver A / Pagano, Livio

Leukemia & lymphoma

2024 Volume 65, Issue 2, Page(s) 199–208

Abstract: Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, ... ...

Abstract	Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
MeSH term(s)	Humans ; COVID-19 ; Pandemics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology ; Hospitalization ; Hematologic Neoplasms
Language	English
Publishing date	2024-01-24
Publishing country	United States
Document type	Journal Article
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.1080/10428194.2023.2280886
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.

van Doesum, Jaap A / Salmanton-García, Jon / Marchesi, Francesco / Di Blasi, Roberta / Falces-Romero, Iker / Cabirta, Alba / Farina, Francesca / Besson, Caroline / Weinbergerová, Barbora / Van Praet, Jens / Schönlein, Martin / López-García, Alberto / Lamure, Sylvain / Guidetti, Anna / De Ramón-Sánchez, Cristina / Batinić, Josip / Gavriilaki, Eleni / Tragiannidis, Athanasios / Tisi, Maria Chiara /

Plantefeve, Gaëtan / Petzer, Verena / Ormazabal-Vélez, Irati / Marques de Almeida, Joyce / Marchetti, Monia / Maertens, Johan / Machado, Marina / Kulasekararaj, Austin / Hernández-Rivas, José-Ángel / Gomes da Silva, Maria / Fernández, Noemí / Espigado, Ildefonso / Drgoňa, Ľuboš / Dragonetti, Giulia / Metafuni, Elisabetta / Calbacho, Maria / Blennow, Ola / Wolf, Dominik / van Anrooij, Bjorn / Nunes Rodrigues, Raquel / Nordlander, Anna / Martín-González, Juan-Alberto / Liévin, Raphaël / Jiménez, Moraima / Gräfe, Stefanie K / García-Sanz, Ramón / Córdoba, Raúl / Rahimli, Laman / van Meerten, Tom / Cornely, Oliver A / Pagano, Livio

Blood advances

2023 Volume 7, Issue 11, Page(s) 2645–2655

Abstract: Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this ... ...

Abstract	Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.
MeSH term(s)	Humans ; COVID-19/therapy ; COVID-19 Testing ; COVID-19 Vaccines ; Immunotherapy, Adoptive ; Retrospective Studies ; SARS-CoV-2 ; Vaccination ; Adaptor Proteins, Signal Transducing ; Antibodies, Monoclonal ; Antigens, CD19
Chemical Substances	COVID-19 Vaccines ; Adaptor Proteins, Signal Transducing ; Antibodies, Monoclonal ; Antigens, CD19
Language	English
Publishing date	2023-04-14
Publishing country	United States
Document type	Multicenter Study ; Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2022009578
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.

Lahmer, Tobias / Salmanton-García, Jon / Marchesi, Francesco / El-Ashwah, Shaimaa / Nucci, Marcio / Besson, Caroline / Itri, Federico / Jaksic, Ozren / Čolović, Natasha / Weinbergerová, Barbora / Seval, Guldane Cengiz / Adžić-Vukičević, Tatjana / Szotkowski, Tomáš / Sili, Uluhan / Dargenio, Michelina / van Praet, Jens / van Doesum, Jaap / Schönlein, Martin / Ráčil, Zdeněk /

Žák, Pavel / Poulsen, Christian Bjørn / Magliano, Gabriele / Jiménez, Moraima / Bonuomo, Valentina / Piukovics, Klára / Dragonetti, Giulia / Demirkan, Fatih / Blennow, Ola / Valković, Toni / Gomes Da Silva, Maria / Maertens, Johan / Glenthøj, Andreas / Fernández, Noemí / Bergantim, Rui / Verga, Luisa / Petzer, Verena / Omrani, Ali S / Méndez, Gustavo-Adolfo / Machado, Marina / Ledoux, Marie-Pierre / Bailén, Rebeca / Duarte, Rafael F / Del Principe, Maria Ilaria / Farina, Francesca / Martín-Pérez, Sonia / Dávila-Valls, Julio / Marchetti, Monia / Bilgin, Yavuz M / Fracchiolla, Nicola S / Cattaneo, Chiara / Espigado, Ildefonso / Cordoba, Raul / Collins, Graham P / Labrador, Jorge / Falces-Romero, Iker / Prezioso, Lucia / Meers, Stef / Passamonti, Francesco / Buquicchio, Caterina / López-García, Alberto / Kulasekararaj, Austin / Ormazabal-Vélez, Irati / Cuccaro, Annarosa / Garcia-Vidal, Carolina / Busca, Alessandro / Navrátil, Milan / de Jonge, Nick / Biernat, Monika M / Guidetti, Anna / Abu-Zeinah, Ghaith / Samarkos, Michail / Anastasopoulou, Amalia / de Ramón, Cristina / González-López, Tomás José / Hoenigl, Martin / Finizio, Olimpia / Pinczés, László Imre / Ali, Natasha / Vena, Antonio / Tascini, Carlo / Stojanoski, Zlate / Merelli, Maria / Emarah, Ziad / Kohn, Milena / Barać, Aleksandra / Mladenović, Miloš / Mišković, Bojana / Ilhan, Osman / Çolak, Gökçe Melis / Čerňan, Martin / Gräfe, Stefanie K / Ammatuna, Emanuele / Hanakova, Michaela / Víšek, Benjamín / Cabirta, Alba / Nordlander, Anna / Nunes Rodrigues, Raquel / Hersby, Ditte Stampe / Zambrotta, Giovanni Paolo Maria / Wolf, Dominik / Núñez-Martín-Buitrago, Lucía / Arellano, Elena / Aiello, Tommaso Francesco / García-Sanz, Ramón / Prattes, Juergen / Egger, Matthias / Limongelli, Alessandro / Bavastro, Martina / Cvetanoski, Milche / Dibos, Miriam / Rasch, Sebastian / Rahimli, Laman / Cornely, Oliver A / Pagano, Livio

Infection

2024

Language	English
Publishing date	2024-02-22
Publishing country	Germany
Document type	Journal Article
ZDB-ID	185104-4
ISSN	1439-0973 ; 0300-8126 ; 0173-2129
ISSN (online)	1439-0973
ISSN	0300-8126 ; 0173-2129
DOI	10.1007/s15010-023-02169-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 881: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 528: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.

Blennow, Ola / Salmanton-García, Jon / Nowak, Piotr / Itri, Federico / Van Doesum, Jaap / López-García, Alberto / Farina, Francesca / Jaksic, Ozren / Pinczés, László Imre / Bilgin, Yavuz M / Falces-Romero, Iker / Jiménez, Moraima / Ormazabal-Vélez, Irati / Weinbergerová, Barbora / Duléry, Rémy / Stojanoski, Zlate / Lahmer, Tobias / Fernández, Noemí / Hernández-Rivas, José-Ángel /

Petzer, Verena / De Jonge, Nick / Glenthøj, Andreas / De Ramón, Cristina / Biernat, Monika M / Fracchiolla, Nicola / Aujayeb, Avinash / Van Praet, Jens / Schönlein, Martin / Méndez, Gustavo-Adolfo / Cattaneo, Chiara / Guidetti, Anna / Sciumè, Mariarita / Ammatuna, Emanuele / Cordoba, Raul / García-Poutón, Nicole / Gräfe, Stefanie / Cabirta, Alba / Wolf, Dominik / Nordlander, Anna / García-Sanz, Ramón / Delia, Mario / Berg Venemyr, Caroline / Brones, Clara / Di Blasi, Roberta / De Kort, Elizabeth / Meers, Stef / Lamure, Sylvain / Serrano, Laura / Merelli, Maria / Coppola, Nicola / Bergantim, Rui / Besson, Caroline / Kohn, Milena / Petiti, Jessica / Garcia-Vidal, Carolina / Dargenio, Michelina / Danion, François / Machado, Marina / Bailén-Almorox, Rebeca / Hoenigl, Martin / Dragonetti, Giulia / Chai, Louis Yi Ann / Kho, Chi Shan / Bonanni, Matteo / Liévin, Raphaël / Marchesi, Francesco / Cornely, Oliver A / Pagano, Livio

American journal of hematology

2022 Volume 97, Issue 8, Page(s) E312–E317

MeSH term(s)	COVID-19 ; Hematologic Neoplasms ; Humans ; SARS-CoV-2 ; Surveys and Questionnaires
Language	English
Publishing date	2022-06-28
Publishing country	United States
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.26626
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA).

Marchesi, Francesco / Salmanton-García, Jon / Emarah, Ziad / Piukovics, Klára / Nucci, Marcio / López-García, Alberto / Ráčil, Zdeněk / Farina, Francesca / Popova, Marina / Zompi, Sofia / Audisio, Ernesta / Ledoux, Marie-Pierre / Verga, Luisa / Weinbergerová, Barbora / Szotkovski, Tomas / Da Silva, Maria Gomes / Fracchiolla, Nicola / De Jonge, Nick / Collins, Graham /

Marchetti, Monia / Magliano, Gabriele / García-Vidal, Carolina / Biernat, Monika M / Van Doesum, Jaap / Machado, Marina / Demirkan, Fatih / Al-Khabori, Murtadha / Žák, Pavel / Víšek, Benjamín / Stoma, Igor / Méndez, Gustavo-Adolfo / Maertens, Johan / Khanna, Nina / Espigado, Ildefonso / Dragonetti, Giulia / Fianchi, Luana / Del Principe, Maria Ilaria / Cabirta, Alba / Ormazabal-Vélez, Irati / Jaksic, Ozren / Buquicchio, Caterina / Bonuomo, Valentina / Batinić, Josip / Omrani, Ali S / Lamure, Sylvain / Finizio, Olimpia / Fernández, Noemí / Falces-Romero, Iker / Blennow, Ola / Bergantim, Rui / Ali, Natasha / Win, Sein / Van Praet, Jens / Tisi, Maria Chiara / Shirinova, Ayten / Schönlein, Martin / Prattes, Juergen / Piedimonte, Monica / Petzer, Verena / Navrátil, Milan / Kulasekararaj, Austin / Jindra, Pavel / Sramek, Jiří / Glenthøj, Andreas / Fazzi, Rita / De Ramón-Sánchez, Cristina / Cattaneo, Chiara / Calbacho, Maria / Bahr, Nathan C / El-Ashwah, Shaimaa / Cordoba, Raul / Hanakova, Michaela / Zambrotta, Giovanni / Sciumè, Mariarita / Booth, Stephen / Rodrigues, Raquel Nunes / Sacchi, Maria Vittoria / García-Poutón, Nicole / Martín-González, Juan-Alberto / Khostelidi, Sofya / Gräfe, Stefanie / Rahimli, Laman / Ammatuna, Emanuele / Busca, Alessandro / Corradini, Paolo / Hoenigl, Martin / Klimko, Nikolai / Koehler, Philipp / Pagliuca, Antonio / Passamonti, Francesco / Cornely, Oliver A / Pagano, Livio

Haematologica

2023 Volume 108, Issue 1, Page(s) 22–33

Abstract: Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed ... ...

Abstract	Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
MeSH term(s)	Humans ; Adult ; Follow-Up Studies ; COVID-19 Testing ; COVID-19 ; Leukemia, Myeloid, Acute/therapy ; Leukemia, Myeloid, Acute/drug therapy ; Hematology
Language	English
Publishing date	2023-01-01
Publishing country	Italy
Document type	Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2022.280847
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry.

Musto, Pellegrino / Salmanton-García, Jon / Sgherza, Nicola / Bergantim, Rui / Farina, Francesca / Glenthøj, Andreas / Cengiz Seval, Guldane / Weinbergerová, Barbora / Bonuomo, Valentina / Bilgin, Yavuz M / van Doesum, Jaap / Jaksic, Ozren / Víšek, Benjamín / Falces-Romero, Iker / Marchetti, Monia / Dávila-Valls, Julio / Martín-Pérez, Sonia / Nucci, Marcio / López-García, Alberto /

Itri, Federico / Buquicchio, Caterina / Verga, Luisa / Piukovics, Klára / Navrátil, Milan / Collins, Graham P / Jiménez, Moraima / Fracchiolla, Nicola S / Labrador, Jorge / Prezioso, Lucia / Rossi, Elena / Čolović, Natasha / Meers, Stef / Kulasekararaj, Austin / Cuccaro, Annarosa / Blennow, Ola / Valković, Toni / Sili, Uluhan / Ledoux, Marie-Pierre / Batinić, Josip / Passamonti, Francesco / Machado, Marina / Duarte, Rafael F / Poulsen, Christian Bjørn / Méndez, Gustavo-Adolfo / Espigado, Ildefonso / Demirkan, Fatih / Čerňan, Martin / Cattaneo, Chiara / Petzer, Verena / Magliano, Gabriele / Garcia-Vidal, Carolina / El-Ashwah, Shaimaa / Gomes-Da-Silva, Maria / Vena, Antonio / Ormazabal-Vélez, Irati / van Praet, Jens / Dargenio, Michelina / De-Ramón, Cristina / Del Principe, Maria Ilaria / Marques-De-Almeida, Joyce / Wolf, Dominik / Szotkowski, Tomáš / Obr, Aleš / Çolak, Gökçe Melis / Nordlander, Anna / Izuzquiza, Macarena / Cabirta, Alba / Zambrotta, Giovanni Paolo Maria / Cordoba, Raul / Žák, Pavel / Ammatuna, Emanuele / Mayer, Jiří / Ilhan, Osman / García-Sanz, Ramón / Quattrone, Martina / Arellano, Elena / Nunes-Rodrigues, Raquel / Emarah, Ziad / Aiello, Tommaso Francesco / Hanakova, Michaela / Ráčil, Zdeněk / Bavastro, Martina / Limongelli, Alessandro / Rahimli, Laman / Marchesi, Francesco / Cornely, Oliver A / Pagano, Livio

Hematological oncology

2023 Volume 42, Issue 1, Page(s) e3240

Abstract: Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and ... ...

Abstract	Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 10
MeSH term(s)	Humans ; COVID-19 ; SARS-CoV-2 ; Pandemics ; Multiple Myeloma/therapy ; Registries
Language	English
Publishing date	2023-12-04
Publishing country	England
Document type	Journal Article
ZDB-ID	604884-5
ISSN	1099-1069 ; 0278-0232
ISSN (online)	1099-1069
ISSN	0278-0232
DOI	10.1002/hon.3240
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1816: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.

Salmanton-García, Jon / Marchesi, Francesco / Gomes da Silva, Maria / Farina, Francesca / Dávila-Valls, Julio / Bilgin, Yavuz M / Glenthøj, Andreas / Falces-Romero, Iker / Van Doesum, Jaap / Labrador, Jorge / Buquicchio, Caterina / El-Ashwah, Shaimaa / Petzer, Verena / Van Praet, Jens / Schönlein, Martin / Dargenio, Michelina / Méndez, Gustavo-Adolfo / Meers, Stef / Itri, Federico /

Giordano, Antonio / Pinczés, László Imre / Espigado, Ildefonso / Stojanoski, Zlate / López-García, Alberto / Prezioso, Lucia / Jaksic, Ozren / Vena, Antonio / Fracchiolla, Nicola S / González-López, Tomás José / Colović, Natasa / Delia, Mario / Weinbergerová, Barbora / Marchetti, Monia / Marques de Almeida, Joyce / Finizio, Olimpia / Besson, Caroline / Biernat, Monika M / Valković, Toni / Lahmer, Tobias / Cuccaro, Annarosa / Ormazabal-Vélez, Irati / Batinić, Josip / Fernández, Noemí / De Jonge, Nick / Tascini, Carlo / Anastasopoulou, Amalia N / Duléry, Rémy / Del Principe, Maria Ilaria / Plantefeve, Gaëtan / Papa, Mario Virgilio / Nucci, Marcio / Jiménez, Moraima / Aujayeb, Avinash / Hernández-Rivas, José-Ángel / Merelli, Maria / Cattaneo, Chiara / Blennow, Ola / Nordlander, Anna / Cabirta, Alba / Varricchio, Gina / Sacchi, Maria Vittoria / Cordoba, Raul / Arellano, Elena / Gräfe, Stefanie K / Wolf, Dominik / Emarah, Ziad / Ammatuna, Emanuele / Hersby, Ditte Stampe / Martín-Pérez, Sonia / Nunes Rodrigues, Raquel / Rahimli, Laman / Pagano, Livio / Cornely, Oliver A

EClinicalMedicine

2023 Volume 58, Page(s) 101939

Abstract: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ ... ...

Abstract	Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan-Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448-4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619-8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093-0.732) and obesity (aOR 0.105, 95%CI 0.014-0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation: Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir. Funding: EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
Language	English
Publishing date	2023-04-06
Publishing country	England
Document type	Journal Article
ISSN	2589-5370
ISSN (online)	2589-5370
DOI	10.1016/j.eclinm.2023.101939
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.

Pagano, Livio / Salmanton-García, Jon / Marchesi, Francesco / Blennow, Ola / Gomes da Silva, Maria / Glenthøj, Andreas / van Doesum, Jaap / Bilgin, Yavuz M / López-García, Alberto / Itri, Federico / Nunes Rodrigues, Raquel / Weinbergerová, Barbora / Farina, Francesca / Dragonetti, Giulia / Berg Venemyr, Caroline / van Praet, Jens / Jaksic, Ozren / Valković, Toni / Falces-Romero, Iker /

Martín-Pérez, Sonia / Jiménez, Moraima / Dávila-Valls, Julio / Schönlein, Martin / Ammatuna, Emanuele / Meers, Stef / Delia, Mario / Stojanoski, Zlate / Nordlander, Anna / Lahmer, Tobias / Imre Pinczés, László / Buquicchio, Caterina / Piukovics, Klára / Ormazabal-Vélez, Irati / Fracchiolla, Nicola / Samarkos, Michail / Méndez, Gustavo-Adolfo / Hernández-Rivas, José-Ángel / Espigado, Ildefonso / Cernan, Martin / Petzer, Verena / Lamure, Sylvain / di Blasi, Roberta / Marques de Almedia, Joyce / Dargenio, Michelina / Biernat, Monika M / Sciumè, Mariarita / de Ramón, Cristina / de Jonge, Nick / Batinić, Josip / Aujayeb, Avinash / Marchetti, Monia / Fouquet, Guillemette / Fernández, Noemí / Zambrotta, Giovanni / Sacchi, Maria Vittoria / Guidetti, Anna / Demirkan, Fatih / Prezioso, Lucia / Ráčil, Zdeněk / Nucci, Marcio / Mladenović, Miloš / Liévin, Raphaël / Hanáková, Michaela / Gräfe, Stefanie / Sili, Uluhan / Machado, Marina / Cattaneo, Chiara / Adžić-Vukičević, Tatjana / Verga, Luisa / Labrador, Jorge / Rahimli, Laman / Bonanni, Matteo / Passamonti, Francesco / Pagliuca, Antonio / Corradini, Paolo / Hoenigl, Martin / Koehler, Philipp / Busca, Alessandro / Cornely, Oliver A

Blood

2022 Volume 140, Issue 26, Page(s) 2773–2787

Abstract: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and ... ...

Abstract	Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
MeSH term(s)	Adult ; Humans ; COVID-19/epidemiology ; COVID-19/prevention & control ; SARS-CoV-2 ; COVID-19 Testing ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/therapy ; Antibodies, Monoclonal ; Antiviral Agents ; Antibodies, Viral
Chemical Substances	Antibodies, Monoclonal ; Antiviral Agents ; Antibodies, Viral
Language	English
Publishing date	2022-09-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2022017257
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey.

Cattaneo, Chiara / Salmanton-García, Jon / Marchesi, Francesco / El-Ashwah, Shaimaa / Itri, Federico / Weinbergerová, Barbora / Gomes Da Silva, Maria / Dargenio, Michelina / Dávila-Valls, Julio / Martín-Pérez, Sonia / Farina, Francesca / Van Doesum, Jaap / Valković, Toni / Besson, Caroline / Poulsen, Christian Bjørn / López-García, Alberto / Žák, Pavel / Schönlein, Martin / Piukovics, Klára /

Jaksic, Ozren / Cabirta, Alba / Ali, Natasha / Sili, Uluhan / Fracchiolla, Nicola / Dragonetti, Giulia / Adžić-Vukičević, Tatjana / Marchetti, Monia / Machado, Marina / Glenthøj, Andreas / Finizio, Olimpia / Demirkan, Fatih / Blennow, Ola / Tisi, Maria Chiara / Omrani, Ali S / Navrátil, Milan / Ráčil, Zdeněk / Novák, Jan / Magliano, Gabriele / Jiménez, Moraima / Garcia-Vidal, Carolina / Erben, Nurettin / Del Principe, Maria Ilaria / Buquicchio, Caterina / Bergantim, Rui / Batinić, Josip / Al-Khabori, Murtadha / Verga, Luisa / Szotkowski, Tomáš / Samarkos, Michail / Ormazabal-Vélez, Irati / Meers, Stef / Maertens, Johan / Pinczés, László Imre / Hoenigl, Martin / Drgoňa, Ľuboš / Cuccaro, Annarosa / Bilgin, Yavuz M / Aujayeb, Avinash / Rahimli, Laman / Gräfe, Stefanie / Sciumè, Mariarita / Mladenović, Miloš / Çolak, Gökçe Melis / Sacchi, Maria Vittoria / Nordlander, Anna / Berg Venemyr, Caroline / Hanáková, Michaela / García-Poutón, Nicole / Emarah, Ziad / Zambrotta, Giovanni Paolo Maria / Nunes Rodrigues, Raquel / Cordoba, Raul / Méndez, Gustavo-Adolfo / Biernat, Monika M / Cornely, Oliver A / Pagano, Livio

Cancers

2022 Volume 14, Issue 22

Abstract: Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients ...

Abstract	Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
Language	English
Publishing date	2022-11-10
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14225530
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito